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Prognostic factors can be dichotomous by nature, but are more
often either polytomous or continuous. Continuous variables are
almost always used in prognostic models after categorization.
Categorizing a continuous variable has adverse consequences: it
requires the definition of cutpoints and implies a threshold effect:
the patients immediately above and below the cut off value are
supposed to be less similar than the patients at each end of the
same category. Choosing a single cutpoint will result in a loss of
statistical power in most instances. But many practical or bio
logical reasons lead researchers to use one or several cutpoints in
order to define the therapeutic classification. Different methods
have been proposed to select cutpoints. One is called the optimal
cutpoint method (Hilsenbeck et al, 1992). It is based on the P value
of repeated univariate analyses of the same sample. This method
has been rejected (Hill, 1993; Altman et al, 1994) because it artifi-
cially decreases the P value. Another possibility is to divide
the sample into equal parts (thirds or quintiles for instance)
on the basis of the continuous variable under study, and to evaluate
the risk in each category. 
Quantitative prognostic variables in childhood ALL include the
white blood cell count, peripheral blast cell count, haemoglobin
level, platelet count and age at diagnosis. The prognostic value of
these variables was identified more than 30 years ago (Tivey,
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Summary Many cutpoints have been proposed to categorize continuous variables in childhood acute lymphoblastic leukaemia (white blood
cell count, peripheral blast cell count, haemoglobin level, platelet count and age), and have been used to define therapeutic subgroups. This
variation in the choice of cutpoints leads to a bias called the ‘Will Rogers phenomenon’. The aim of this study was to analyse variations in the
relative risk of relapse or death as a function of continuous prognostic variables in childhood ALL and to discuss the choice of cutpoints. We
studied a population of 1545 children with ALL enrolled in three consecutive protocols named FRALLE 83, FRALLE 87 and FRALLE 89. We
estimated the risk of relapse or death associated with different values of each continuous prognostic variable by dividing the sample into
quintiles of the distribution of the variables. As regards age, a category of children under 1 year of age was distinguished and the rest of the
population was divided into quintiles. The floated variance method was used to calculate the confidence interval of each relative risk, including
the reference category. The relation between the quantitative prognostic factors and the risk was monotonic for each variable, except for age.
For the white blood cell count (WBC), the relation is log linear. The risk associated with WBC values in the upper quintile was 1.9 times higher
than that in the lower quintile. The peripheral blast cell count correlated strongly with WBC (correlation coefficient: 0.99). The risk increased
with the haemoglobin level, and the risk in the upper quintile was 1.3 times higher than that in the lower quintile. The risk decreased as the
platelet count increased: the risk in the lower quintile was 1.2 times higher than that in the upper quintile. The risk increased gradually with
increasing age above one year. The small subgroup of patients (2.5% of the population) under 1 year of age at diagnosis had a risk 2.6 times
higher than the reference category of patients between 3 and 4.3 years of age. When the risk associated with a quantitative prognostic factor
varies monotonously, the selection of a cutpoint is arbitrary and represents a loss of information. Despite this loss of information, such
arbitrary categorization may be necessary to define therapeutic stratification. In that case, consensus cutpoints must be defined if one wants
to avoid the Will Rogers phenomenon. The cutpoints proposed by the Rome workshop and the NCI are arbitrary, but may represent an
acceptable convention. © 2000 Cancer Research Campaign http://www.bjcancer.com
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http://www.bjcancer.com1952; Zuelzer, 1964) and they remain prognostic today despite
improvements in treatment (Reiter et al, 1994). The quantitative
nature of these variables necessitates the use of cutpoints to define
prognostic subgroups and to select a treatment (Mastrangelo,
1986a; Bleyer, 1989). Sometimes a single cutpoint is chosen, but
in other studies several cutpoints are selected, usually in an arbit-
rary manner. The hypotheses underlying the choice of cutpoints
are rarely explained in the literature or discussed. Table 1 shows
examples of the different cutpoints for age and white blood cell
counts chosen by different teams in prognostic studies. The wide
diversity of cutpoints can have significant consequences and
makes it difficult to compare the results of different protocols. The
same patient can be considered as having a low risk or a high risk
depending on the prognostic classification used. Such differences
in classification may lead to an apparent improvement in the
outcome of all the different prognostic risk groups, despite the lack
of any global improvement. This is called the Will Rogers
phenomenon (Feinstein et al, 1985). The purpose of this study,
using a published data set (Donadieu et al, 1998), was to explore
systematically the relationship between continuous prognostic
variables and outcome in childhood ALL. 
MATERIALS AND METHODS 
French acute lymphoblastic leukaemia group (FRALLE)
83, 87 and 89 protocols 
FRALLE 83 (May 1983–September 1986) included 818 patients
from 59 centres, FRALLE 87 (June 1987–March 1989) 361
patients from 37 centres, and FRALLE 89 (April 1989–January
1992) 586 patients from 35 centres. A brief description of the three
protocols can be found in Table 2. The results have been published
elsewhere (Donadieu et al, 1998). 
Exclusion from the study 
Of the 1766 patients included in the three protocols, 221 were
excluded from the present analysis: 3 for errors in the initial 
diagnosis (AML or ALL 3), 21 because they had mediastinal T
lymphoma without bone marrow infiltration, 67 because they did
not live in France, 112 because no baseline data were available
(109 in FRALLE 83, 2 in FRALLE 87 and 1 in FRALLE 89), 9
because their centres failed to provide more than half the baseline
and follow-up data, and two because of constitutional trisomy 21.
7 patients were excluded because at least one of the variables
studied was missing. 
Endpoints, cut-off dates for analysis, and follow-up 
The chosen endpoint was primary failure, toxic death or relapse
at any site. Event-free survival (EFS) was defined as the time
between the diagnosis and the time of the event or the time of the
last examination when no event occurred. If a patient failed to
enter complete remission, the event was recorded as occurring
immediately, and EFS was 0. The cut-off date for the analysis was
September 30, 1999. 
Study variables 
We studied quantitative variables with a known prognostic value
recorded in the FRALLE data base, i.e. age at diagnosis and the
complete blood count. If several blood counts were available at
initial diagnosis, we used the lowest haemoglobin level and
platelet count before any transfusion, and the highest white blood
cell count and peripheral blast cell count. 
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Table 1 Number and values of cutpoints for age and white blood cell counts (WBC) used in the literature to define prognostic
categories in ALL 
Age cutpoints WBC cutpoints 
Cooperative institution (reference) Number Values in years Number Values in 1000/mm3
French group (Jacquillat et al, 1978) 3 1–15–20 1 35 
FRALLE 83 (Schaison et al, 1990) 2 2–10 3 15–50–100 
NOPHO group (Gustafsson et al, 1998) 1 1–2–10  4 10–20–50–100 
Japanese group (Hiyoshi et al, 1985) 4 1–4–6–10 4 5–10–50–200 
CCG 1972–1975 (Robinson et al, 1980) 5 2–4–6–8–10 5 5–10–20–50–100
CCG 160 (Bleyer et al, 1986) 4 1–3–6–10 2 20–50 
BFM before 1981 (Bucsky et al, 1988) 5 0.5–1–1.5–2–10 NA 
BFM 81 (Schrappe et al, 1987) 4 1–2–10–14  3 10–50–100 
BFM 86 (Reiter et al, 1994) 3 1–6–10 4 10–20–50–200 
DFCI 85–01 (Schorin et al, 1994) 3 1–2–9 3 20–50–100 
UKALL X (Chessells et al, 1995) 2 1–10 4 10–20–50–100 
Each cutpoint is included in the interval to the right, for instance cutpoint 1 and 10 for age define the intervals age <1, 1 to 9 and 10+. 
NA: Not available. WBC is indirectly in the model, which included 0.2 Log (peripheral blast cell count +1). 
Table 2 Description of the FRALLE 83, 87 and 89 protocols 
All three protocols included an induction, a consolidation and a maintenance
phase. All patients with ALL and age 0 to 20 years were included. In each
protocol, the treatment was adapted to the level of risk by defining low,
average and high risk groups. The definition of the risk groups was different
in the different protocols, the low risk group being larger in FRALLE 87 and
89 than in FRALLE 83. 
FRALLE 83 protocol compared Vincristine to Vindesine in all patients,
compared standard to intensive consolidation in the intermediate risk group,
and compared testicular irradiation to no irradiation for boys in the high risk
group. 
FRALLE 87 and 89 protocols compared Daunorubicine to Rubidazone in all
patients, and compared 3 to 8 g/m2 of methotrexate in the low-risk group. In
the FRALLE 89 protocol, the dose of folinic acid was reduced to 12 pulses of
15 mg/m2. 
The detailed protocols have been published elsewhere (Donadieu et al,
1998). Statistical methods 
BMDP® software was used for all statistical analyses. Median
follow-up was estimated from a Kaplan–Meier curve in which the
last follow-up date was used for the patients who survived as if it
was an endpoint, and in which the other patients were censored at
the time of death (Schemper and Smith, 1996). The actuarial
method was used to estimate survival rates. A Cox semi-
parametric model was used to estimate the hazard ratio in each
category (Cox, 1972; Collet, 1994). The cutpoints were obtained
by dividing the overall sample into quintiles. A category below 1
year of age corresponding to 39 patients (2.5% of the population)
was defined, as proposed in the literature (Mastrangelo, 1986b;
Smith et al, 1996), and the rest of the population was divided into
quintiles. For each cutpoint, the boundary value was included in
the higher category. The variance of the hazard ratios was calcu-
lated by the floated variance method (Easton et al, 1991), in order
to attribute some imprecision to the reference category. In the
figures, the hazard ratio for each category (after log transformation
for white blood cells) is plotted at the median value of the category
on the x axis. Another Cox regression model estimated the trend in
the log hazard ratios. 
RESULTS 
The median follow-up was 111 months in FRALLE 83, 106
months in FRALLE 87, and 86 months in FRALLE 89. Among the
1545 patients, a total of 781 events were recorded during the study
period, corresponding to 36 toxic deaths during induction, 42
induction failures, 65 toxic deaths after induction (patients in first
remission) and 638 relapses. Complete remissions were obtained
after induction in 1467 patients (95%), while 78 patients (5%)
failed to enter complete remission after the induction phase. 
The 10-year EFS rate was 48.2% (SE 1.3), and the 10-year
survival rate was 61.4% (SE 1.3). 
Age 
The distribution of age was approximately log-normal, with a
median of 5.1 years. The risk of events varied with age according to
a U-shaped curve. The group of patients under one year of age had a
risk 2.6 times higher than that of patients between 3 and 4.3 years of
age (the reference quintile). A Cox regression model with a specific
hazard ratio for the population under one year of age and a linear
trend in the older population was fitted, leading to the estimation: 
HR = exp [1.09(if age < 1 year) + 0.042* (age 3.5)(if age ≥ 1 year)] 
The risk in the highest quintile was 1.6 times higher than that in the
reference quintile Figure 1). 
White blood cell count 
The white blood cell count (WBC) had an exponential distribution
with a median of 12 000/mm3. The risk of relapse or toxic death
increased with increasing WBC (Figure 2). A Cox regression
model was fitted with a linear effect of log (WBC): 
HR = exp [0.158 * (Log (WBC + 0.1) – Log 2.5)] 
where WBC is expressed in 1000/mm3. The risk in the highest
quintile was 1.9 times higher than that in the lowest quintile. 
Peripheral blast cell count 
Peripheral blast cells represent a large proportion of white cells at
diagnosis, and their numbers correlate strongly (r = 0.99). Thus,
the peripheral blast cell count provides the same prognostic in-
formation as the WBC. 
Haemoglobin level 
The distribution of haemoglobin levels at diagnosis was approx-
imately normal, with a median of 7.7 g dl 1. A Cox regression
model was fitted with a linear effect of the haemoglobin level: 
HR = exp [0.037 * (Hb – 4.6)] 
The risk in the highest quintile was 1.3 times higher than that in the
lowest quintile (Figure 3). 
Platelet count 
The distribution of the platelet count was log-normal, with a
median of 56 000/mm3. The hazard ratio of events fell when
platelets increased. A Cox regression model was fitted with a
linear effect of the platelet count: 
HR = exp [– 0.0012 * (Platelet 232)]. 
The risk in the lowest quintile was 1.2 times higher than that in the
highest quintile (Figure 4). 
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Figure 1 Hazard ratio for relapse or death and 95% confidence interval for
age at diagnosis under 1 year and for each quintile of age at diagnosis
above 1 year (using the median value of the quintile on x axis) 
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Figure 2 Hazard ratio for relapse or death and 95% confidence interval for
each quintile of white blood cell count at diagnosis (using the median value
of the quintile on x axis) DISCUSSION 
The main result of our study is that, except for age, the relation
between the risk of relapse or toxic death and each continuous
prognostic factor in childhood ALL is monotonic. The patients
under 1 year of age had a markedly increased risk, while the risk
for patients above 1 year increased linearly with age. Except for
age, the ratio between the risk in the worst quintile and that in the
best quintile never exceeded 2. 
We performed a univariate analysis for each variable dividing
the sample into quintiles. This avoids the optimal cutpoint method
and the associated multiple tests. We used a linear or log linear
model, which is simpler than fractional polynomials (Royston and
Altman, 1994; Sauerbrei, 1999). 
When the risk varies monotonously as a function of a con-
tinuous variable, any categorization of the variable represents a
loss of statistical information, and there is no optimal cutpoint. For
instance, the selection of a cutpoint of 50 000 WBC/mm3 for WBC
is arbitrary, as is the selection of 9 years for age. 
The analysis was not adjusted on other known prognostic vari-
ables. Here, we present an exploratory study of the relation
between the risk of relapse or death and different continuous vari-
ables in childhood acute lymphoblastic leukaemia. A multivariate
analysis using the same data set showed that age and the
white blood cell count were the most significant prognostic vari-
ables in childhood acute lymphoblastic leukaemia, whereas the
haemoglobin level and the platelet count had a lower prognostic
value (Donadieu et al, 1998). 
Many cutpoints have been used in the literature (Table 1) but
this diversity makes it difficult to compare the results of different
protocols. The same patient can be considered as having a low
risk or as having a high risk depending on the prognostic classi-
fication used. Such classification changes may lead to an apparent
improvement in each prognostic risk group, without any overall
improvement (Feinstein et al, 1985). This is illustrated in Figure 5
with a teaching example, and in Figure 6 with our data set. A
consequence is that, overall results from institutions using
different classifications are comparable, whereas results within
prognostic subgroups are not. 
Nevertheless, prognostic subgroups are necessary for clinical
decision making, since the treatment is usually adapted to the risk.
To be able to compare results between institutions within a risk
category, it would be better to agree upon a convention for the
choice of cutpoints, however arbitrary they may be, rather than
1620 J Donadieu et al
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Figure 5 The Will Rogers phenomenon: a teaching example. Note: The
overall 5-year EFS in the sample is 50%. There are three subgroups of
equal size, with 5-years EFS values of 80%, 50% and 20%. The definition of
the ‘low risk’ and ‘high risk’ categories changes between classification 1 and
2, resulting in a shift between the categories of one third of the sample.
Classification 1 leads to a better result in each category (80% and 35% for
the low and high risk group) compared to classification 2 (60% and 20%
respectively), without any change in the overall results 
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Figure 6 The Will Rogers phenomenon: a real example with the FRALLE
data set. Note: The overall 5-year EFS is 52%. The variable used to define
the risk category is the white blood cell count expressed in 1000/mm3.
Classification 1 leads to an apparent improvement in the results for each
category as compared to classification 2. Moving the WBC cutpoint from 5 to
15 moves 30% of the patients from the low-risk group to the standard risk
group. At the other extreme, introducing a cutpoint of 400 identifies a small
subgroup of 2% of patients with a very bad prognosis.
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Figure 3 Hazard ratio for relapse or death and 95% confidence interval for
each quintile of haemoglobin level at diagnosis (using the median value of
the quintile on x axis) 
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Figure 4 Hazard ratio for relapse or death and 95% confidence interval for
each quintile of platelet count at diagnosis (using the median value of the
quintile on x axis) change the values of quantitative variables defining treatment
groups at each new analysis or at each new protocol. 
Two consensus conferences (the Rome workshop (Mastrangelo,
1986b) and the NCI meeting (Smith et al, 1996)) have proposed
cutpoints for age and white blood cells, which represent the most
significant continuous variables (Donadieu et al, 1998). They both
proposed 1 and 9 years, and 50 000 WBC/mm3 as cutpoints for age
and the white blood cell count, respectively. These values are both
arbitrary and acceptable. 
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